Alliant Energy Corporation vs Novartis AG — how do they compare? Alliant Energy Corporation trades at $68.56 (market cap $17.69B), while Novartis AG trades at $153.53 (market cap $298.18B). The key difference: Novartis AG is far larger — about 16.9× Alliant Energy Corporation's market cap, and Alliant Energy Corporation pays the higher dividend (3.14%). Which is the better fit depends on your goals.
| LNT | NVS | |
|---|---|---|
Market Cap | $17.69B | $298.18B |
Sector | Utilities | Health |
52-Week High | $78.03 | $168.62 |
52-Week Low | $63.62 | $119.31 |
Enterprise Value | $29.78B | $339.50B |
Dividend Yield | 3.14% | 3.02% |
Signals from Pluang's Aura AI — not financial advice
LNT trades at $69.37, down 0.22% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported Q2 2026 EPS of $0.65, beating expectations, and maintains strong fundamentals with 18.45% net income margin and 11.14% ROE. Recent news highlights mixed institutional activity and earnings performance influenced by data center demand and cost pressures.
The outlook is balanced with a consensus price target of $77.67 implying upside, supported by earnings beats and a clean energy investment plan. Risks include rising debt levels, cost inflation, and weather-related volatility. Analyst sentiment is positive with no sell ratings, but technical weakness warrants caution near-term.
Novartis (NVS) trades at $156.33, up 1.37% on the day, with a bullish technical signal and strong support near $156. The company reported Q2 2026 earnings that beat expectations, driven by robust oncology drug sales, and reaffirmed full-year guidance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%, while valuation ratios like P/E of 23.61 and P/B of 7.15 reflect premium pricing. Recent news highlights institutional buying and CEO confidence in the growth pipeline.
The outlook for NVS is positive, supported by earnings momentum and a diversified drug portfolio, but risks include generic competition for Entresto and pricing pressures. Analyst consensus is mixed with 24% buy ratings, indicating cautious optimism. Investment appeal hinges on execution of new drug launches and offsetting legacy product declines.
Trailing returns across standard periods
Latest headlines on both assets
Alliant Energy is the parent of two regulated utilities, Interstate Power and Light and Wisconsin Power and Light, serving nearly 1 million electricity and natural gas customers and approximately 420,000 natural gas-only customers. Both subsidiaries engage in the generation and distribution of electricity and the distribution and transportation of natural gas. Alliant also owns a 16% interest in American Transmission Co.
Read more on LNT →Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →